*From the Authors*:

We appreciate the opportunity to respond to Dr. Kyle-Sidell's letter regarding our article on coronavirus disease (COVID-19) lung injury and high-altitude pulmonary edema (HAPE) ([@bib1]). Although we agree it is necessary to identify the best means for treating respiratory failure due to COVID-19, we believe it is important to highlight some important misconceptions and address broader concerns raised within the letter.

With regard to misconceptions, the author writes that our claims about the natural evolution of lung injury in COVID-19 have not been confirmed and are erroneously based on a presumption of equivalence between COVID-19 and other causes of acute respiratory distress syndrome (ARDS). This statement overlooks the fact that the majority of patients in published series meet the Berlin definition of ARDS ([@bib2], [@bib3]) and that published autopsy results ([@bib4], [@bib5]), early autopsy results in preprint form, and autopsy studies from related coronavirus infections---severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus---document the presence of hyaline membranes and other findings consistent with diffuse alveolar damage, the histopathological correlate of the pathophysiology we cite and the hallmark of ARDS. Vascular lesions, including microthrombi, have been noted, but these findings are entirely consistent with prior reports on non-COVID ARDS ([@bib6]).

The author also refers to hypocapnic hypoxemia manifesting as hypoxemia out of proportion to dyspnea as a "most striking and unusual similarity" between HAPE and COVID-19. In fact, the absence of dyspnea is uncommon in HAPE, and hypocapnia is a highly common finding in many causes of both acute and chronic hypoxemic respiratory failure. Hypoxemia stimulates peripheral chemoreceptor output, which in turn increases minute ventilation. Together with stimulation to ventilation from other factors, including fear, fever, sympathetic nervous system activation, and lung inflammation, this augments CO~2~ elimination from uninvolved areas of the lung and causes hypocapnia. The presence of hypocapnic hypoxemia is nonspecific, and its presence in HAPE and COVID-19 in no way implies a shared pathophysiology.

Finally, the author states, without supporting evidence, that patients with COVID-19 have "normal or near-normal pulmonary compliance." To date, only three published reports have documented static compliance in COVID-19, and in two of them ([@bib2], [@bib3]) the average static compliance was low (\<35 ml/cm H~2~O) and consistent with that seen in prior studies of ARDS. Although the recent letter from Gattinoni and colleagues ([@bib7]) reports a higher average of 50 m/cm H~2~O, it is apparent from the letter's accompanying figure that some patients had markedly decreased compliance. Furthermore, compliance values of 50 ml/cm H~2~O, which are about half those seen in healthy, spontaneously breathing individuals (100 cm/H~2~O) and, therefore, not normal, have actually been seen in patients in prior large ARDS cohorts ([@bib8]).

On a broader level, the author seems to imply that all of the severe pathology in COVID-19 lung injury is related to ventilator-induced lung injury (VILI) rather than evolution of the disease. There are no published data to support this assertion. The compliance data from the two reports noted above ([@bib2], [@bib3]) were obtained on the first day of mechanical ventilation, which would indicate that severe injury was present in many of these patients at the time of intubation. Furthermore, the fact that the majority of patients with other indications for invasive mechanical ventilation do not progress to ARDS ([@bib9]) argues against the notion that VILI is an inevitable outcome of mechanical ventilation under all circumstances, including COVID-19. Thus, although VILI has long been a clinical concern, the problem is not initiation of mechanical ventilation *per se* but rather initiation of inappropriate mechanical ventilation strategies, including an overly high tidal volume or distending pressure.

Although we agree with Dr. Kyle-Sidell about the importance of scientific debate, our ultimate concern with the author's letter and statements in other forums is that these and other claims about COVID-19 pathophysiology, such as the predominance of endothelial over epithelial injury, lack supporting evidence and are contradicted by the published physiologic, histopathologic, and radiographic evidence. In a time of high patient volumes and stress, there arises a risk that clinicians will latch onto such claims and abandon the approach to ARDS care that has been developed over many years of well-designed, well-controlled randomized clinical trials, which have yielded impressive improvements in mortality and other clinical outcomes. When faced with new diseases and clinical challenges, we should recognize that novel observations and hypotheses are important for advancing care. We must, however, keep the focus on conducting well-designed studies of these ideas so that we can come out on the other end of the pandemic with a solid sense of what does and does not work. Action based simply on conjecture and unsubstantiated claims will leave us with more uncertainty and may increase the risk of patient harm.
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